News Search Results
May 05, 2026, 20:28 ET MingMed Biotechnology presenta datos positivos de QA102 oral para la degeneración macular asociada a la edad
- MingMed Biotechnology presenta datos positivos de la fase II de QA102 oral para el tratamiento de la degeneración macular asociada a la edad (DMAE) intermedia en la Asociación para la Investigación en Visión y Oftalmología (ARVO) 2026GUANGZHOU, China,
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 5, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology präsentiert auf der Tagung der Association for Research in Vision and Ophthalmology (ARVO) 2026 positive Phase-II-Daten zum oralen Wirkstoff QA102 für die Behandlung der intermediären altersbedingten Makuladegeneration (AMD)
GUANGZHOU, China, 6. Mai 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, ein biomedizinisches Unternehmen, das sich auf die Erforschung und Entwicklung neuartiger Therapeutika in verschiedenen Therapiebereichen konzentriert,
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)
GUANGZHOU, Chine, 6 mai 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, une société biomédicale axée sur la découverte et le développement de nouveaux traitements dans plusieurs domaines thérapeutiques, a annoncé les résultats
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:10 ET Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
https://eco2026.org/.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
May 05, 2026, 17:11 ET Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that
More news about: Curis, Inc.
May 05, 2026, 16:30 ET Corteva Delivers Strong 1Q 2026, Reaffirms 2026 Outlook, On-Track for 4Q 2026 Separation
commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) effect of changes in agricultural and related policies
More news about: Corteva Agriscience
May 05, 2026, 16:15 ET Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
CAMBRIDGE, Mass., May 5, 2026 /PRNewswire/ -- Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation
More news about: Factor Bioscience
May 05, 2026, 16:01 ET Rigel Reports First Quarter 2026 Financial Results
Calif., May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the first quarter ended March 31, 2026, including sales
More news about: Rigel Pharmaceuticals, Inc.
May 05, 2026, 13:53 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
May 05, 2026, 12:41 ET Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Pharmaceuticals, Inc.
May 05, 2026, 11:48 ET Alcami Completes Acquisition of Tjoapack
www.alcami.com.About TjoapackTjoapack is a global contract packaging organization (CPO) serving the pharmaceutical and biotechnology industries, with more than 35 years of experience in regulated pharmaceutical packaging. Founded in 1989 and headquartered in The Netherlands, the
More news about: Alcami
May 05, 2026, 10:05 ET Creatv Announces Five Clinical Data Presentations at ASCO 2026
multi-analyte cell subtyping prior to systemic therapy.Abstract: e15525Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer. Abstract Title:
More news about: Creatv MicroTech, Inc.
May 05, 2026, 09:00 ET Made Scientific and RoosterBio Announce Strategic Technology and Supply Partnership to Expand Scalable MSC and Extracellular Vesicle Manufacturing
deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit
More news about: Made Scientific, Inc.
May 05, 2026, 09:00 ET RoosterBio and Made Scientific Announce Strategic Technology and Supply Partnership to Expand Scalable MSC and Extracellular Vesicle Manufacturing
deliver reliable and scalable solutions, supported by their long-term strategic backer, GC Corporation, a global leader in the pharmaceutical and biotechnology sectors. For more information, visit
More news about: RoosterBio, Inc.
May 05, 2026, 09:00 ET New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced two significant new studies presented at Digestive Disease Week (DDW) 2026, taking place May 3-5, 2026.
More news about: Phenomix Sciences
May 05, 2026, 08:55 ET Pacific Hybreed Closes $1 Million Round with Support from Hawaiʻi Angels and Blue Startups to Scale Resilient Shellfish Production
KAILUA-KONA AND HONOLULU, Hawaii, May 5, 2026 /PRNewswire/ -- Pacific Hybreed, a Big Island-based aquaculture biotechnology company, today announced the close of a $1 million funding round with participation from Hawaiʻi Angels and Blue Startups.
More news about: Hawaiʻi Angels
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD). Elaaj Bio is a wholly owned subsidiary of the Loulou
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused on development of transformative treatments for CDKL5 Deficiency Disorder (CDD). Elaaj Bio is a wholly owned subsidiary of the Loulou
More news about: Viralgen
May 05, 2026, 08:00 ET Elaris Advances C. difficile Vaccine Beyond Toxin-Only Approaches with Matrivax Asset Acquisition
FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced that it has entered into an asset purchase agreement with Matrivax Research & Development Corporation ("Matrivax"), a U.S.-based biotechnology company, to acquire intellectual
More news about: Elaris
May 05, 2026, 08:00 ET Apertura Gene Therapy and the TSC Alliance Announce Collaboration to Advance Gene Therapy Programs Designed to Treat Tuberous Sclerosis Complex (TSC)
NEW YORK AND SILVER SPRING, Md., May 5, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, and the TSC Alliance, an internationally recognized nonprofit that
More news about: Apertura Gene Therapy
May 05, 2026, 06:59 ET Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
WALTHAM, Mass., May 5, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today reported financial
More news about: Q32 Bio
May 05, 2026, 06:45 ET Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
May 05, 2026, 06:36 ET MEDP Legal Alert: Medpace Hit with Securities Fraud Class Action Over Cancellation Rates and Corresponding 16% Stock Drop
Fraud?Medpace is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. During the relevant period, Medpace allegedly misled investors concerning its
More news about: Bleichmar Fonti & Auld LLP